SynBioBeta Speaker
Inhwan Kim
Enveda
CSO
Inhwan Kim has diverse experience across provider, payor, and investor roles, which provides him with a unique cross-functional perspective at the intersection of science, finance, and healthcare strategy. Most recently, he managed the portfolio at BridgeBio, where he prioritized investments and ensured cohesive strategies across multiple drug development initiatives. Previously, he served as a consultant at McKinsey & Company, advising biotechs, pharmaceutical firms and global health authorities. Inhwan holds a Pharm.D. from Rutgers University and an MBA from The Kellogg School of Management at Northwestern University.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Inhwan
This Year
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
